^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Progesterone receptor agonist

    Related drugs:
    5d
    PROGENDO: Impact of Different Doses and Routes of Exogenous Progesterone Administration on Endometrial Receptivity Parameters (clinicaltrials.gov)
    P4, N=109, Completed, Instituto Valenciano de Infertilidad, IVI VALENCIA | Recruiting --> Completed | Trial primary completion date: Dec 2025 --> Apr 2025
    Trial completion • Trial primary completion date
    8d
    A prospective, randomized, parallel controlled clinical trial of megestrol acetate oral suspension in patients with locally advanced nasopharyngeal carcinoma (ChiCTR2500114759)
    P=N/A, N=68, Not yet recruiting, Fujian Cancer Hospital; Fujian Cancer Hospital
    New trial
    |
    megestrol • TheraCIM (nimotuzumab)
    8d
    A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients with Cancer Cachexia (ChiCTR2500112934)
    P=N/A, N=495, Not yet recruiting, Henan Cancer Hospital; Henan Cancer Hospital
    New trial
    |
    megestrol
    8d
    Comparison of the effects of ultrasound-guided puncture sclerotherapy and laparoscopic surgery combined with danazol on ovarian function in the treatment of ovarian endometriosis (ChiCTR2500112158)
    P=N/A, N=40, Not yet recruiting, Peking University Shenzhen Hospital; Peking University Shenzhen Hospital
    New trial
    8d
    Ovulation induction with oral contraception alone in biochemical to overt primary ovarian insufficiency: a pilot study. (ChiCTR2500111618)
    P=N/A, N=32, Not yet recruiting, Xiangya Hospital, Central South University; Xiangya Hospital, Central South University
    New trial
    8d
    A study on the correlation of drug metabolism and human body composition based on the bioequivalence trial of Progesterone Sustained-release vaginal gel (ChiCTR2500115150)
    P=N/A, N=48, Completed, The Second Affiliated Hospital of Wenzhou Medical University; The Second Affiliated Hospital of Wenzhou Medical University
    New trial
    8d
    A Multicenter, Randomized, Controlled Phase II Clinical Trial of Nanocrystalline Megestrol Acetate versus Placebo for Anorexia in Patients with Unresectable Hepatocellular Carcinoma Receiving TACE Combined with Targeted and Immunotherapy (ChiCTR2600117241)
    P2, N=88, Not yet recruiting, Southern Medical University Southern Hospital; Southern Medical University Southern Hospital
    New P2 trial
    |
    megestrol
    10d
    The role of PAQR3 in cancer progression - Molecular regulation, signaling pathways, and clinical implications: A review. (PubMed, Biomol Biomed)
    Progesterone and adiponectin receptor 3 (PAQR3) is a Golgi-localized seven-transmembrane protein that anchors rapidly accelerated fibrosarcoma kinase (Raf) and suppresses rat sarcoma/rapidly accelerated fibrosarcoma/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (Ras/Raf/MEK/ERK) signaling, thereby influencing cellular proliferation, differentiation, and metastasis...These effects are modulated by upstream regulators, including microRNA-543 (miR-543), circular RNA 0043280/microRNA-203a-3p (circ_0043280/miR-203a-3p), microRNA-15b (miR-15b), human epidermal growth factor receptor 2 (HER2), 5-aza-2'-deoxycytidine (5-Aza-CdR), autophagy-related 7 (ATG7), and damage-specific DNA binding protein 2 (DDB2). In conclusion, PAQR3 functions as a tumor suppressor and holds potential as a prognostic biomarker. Targeting PAQR3-related pathways may provide new therapeutic opportunities.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • MIR543 (MicroRNA 543) • DDB2 (Damage Specific DNA Binding Protein 2) • ATG7 (Autophagy Related 7) • MIR15B (MicroRNA 15b) • MIR203A (MicroRNA 203a)
    13d
    Analysis of the Relationship Between Early Estrogen Response and Cryptorchidism. (PubMed, Endocr Metab Immune Disord Drug Targets)
    This study provided translational insights, enhancing the current understanding of testicular pathogenesis and contributing to the diagnosis and treatment of cryptorchidism.
    Journal
    |
    SPI1 (Spi-1 Proto-Oncogene)
    16d
    Sex hormones and tuberculosis: Implications for immune regulation, susceptibility, and disease pathogenesis. (PubMed, Tuberculosis (Edinb))
    Increasing evidence indicates that sex steroid hormones estrogen, progesterone, and testosterone modulate immune responses critical for MTB control...However, circulating hormone data in TB patients are inconsistent, highlighting the need for longitudinal, hormone-aware studies. Overall, sex hormone mediated immune modulation influences TB susceptibility and pathogenesis, and future research should adopt sex and hormone-dose-aware designs to optimize host-directed therapies.
    Review • Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • IL5 (Interleukin 5)
    16d
    Case Report: Pembrolizumab associated lichen planus in early stage triple negative breast cancer. (PubMed, Front Oncol)
    Triple negative breast cancer (TNBC) is a breast cancer with a poor prognosis, marked by the absence of estrogen (ER) and progesterone (PR) receptors as well as human epidermal growth factor receptor (HER2) expression. Several skin-related side effects have been documented, such as pruritus, maculopapular rashes, vitiligo, lichenoid skin reactions, psoriasis, and, in rare cases, severe and potentially life-threatening conditions. We report a rare case of pembrolizumab-associated lichen planus in a 43-year-old woman who received pembrolizumab for neoadjuvant treatment of TNBC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PD-L2 (Programmed Cell Death 1 Ligand 2)
    |
    HER-2 expression
    |
    Keytruda (pembrolizumab)
    17d
    Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P3, N=68, Not yet recruiting, Changchun GeneScience Pharmaceutical Co., Ltd.
    New P3 trial
    |
    megestrol